Exemestane: tested in a combination
77 studies: another drug in the study is under test too. Page 1 of 1. Open to participants first (19), then studies with results posted, then the rest; newest registration first within each.
- Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast CancerNot yet recruitingNCT07826052Phase 2Report a problem
- Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast CancerNot yet recruitingNCT07499999Phase 2Report a problem
- A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast CancerRecruitingNCT07483307Phase 2Report a problem
- Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)RecruitingNCT07395336Phase 2Report a problem
- An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast CancerNot yet recruitingNCT07299890Phase 2Report a problem
- De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority TrialNot yet recruitingNCT07153757Phase 3Report a problem
- Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer PatientsRecruitingNCT07071038Phase 2Report a problem
- Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast CancerNot yet recruitingNCT07005557Phase 3Report a problem
- ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast CancerRecruitingNCT06970912Phase 2Report a problem
- Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)RecruitingNCT06656624Phase 2Report a problem
- Pre-Operative Window of ET to Inform RT Decisions (POWER II)RecruitingNCT06507618Phase 3Report a problem
- Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.RecruitingNCT06364267Phase 2Report a problem
- Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast CancerRecruitingNCT06361940Phase 2Report a problem
- Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast CancerNot yet recruitingNCT06223698Phase 3Report a problem
- Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)RecruitingNCT05861830Phase 3Report a problem
- Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low RiskRecruitingNCT05297617Phase 2Report a problem
- Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast CancerRecruitingNCT04023292Phase 2Report a problem
- Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)RecruitingNCT03624244Phase 2Report a problem
- Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScoreRecruitingNCT02476786Phase 2Report a problem
- A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic CancerTerminatedNCT06630325Phase 2Results postedReport a problem
- Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell TumorsCompletedNCT06169124Phase 2Results postedReport a problem
- Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast CancerActive, not recruitingNCT04272801Phase 2Results postedReport a problem
- The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast CancerCompletedNCT04129216Phase 2Results postedReport a problem
- Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast CancerCompletedNCT03219476Phase 2Results postedReport a problem
- Genomic Based Assignment of Therapy in Advanced Urothelial CarcinomaCompletedNCT02788201Phase 2Results postedReport a problem
- ER Reactivation Therapy for Breast CancerCompletedNCT02188745Phase 2Results postedReport a problem
- Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase InhibitorsCompletedNCT02028507Phase 3Results postedReport a problem
- Exemestane and Cyclophosphamide for Metastatic Breast CancerCompletedNCT01963481Phase 2Results postedReport a problem
- Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 TumorsCompletedNCT01831076Phase 2Results postedReport a problem
- Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02CompletedNCT00659373Phase 3Results postedReport a problem
- Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer PatientsCompletedNCT00432172Phase 2Results postedReport a problem
- Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast CancerCompletedNCT00265759Phase 3Results postedReport a problem
- Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast CancerCompletedNCT00201864Phase 2Results postedReport a problem
- Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast CancerCompletedNCT00201773Phase 2Results postedReport a problem
- Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast CancerTerminatedNCT00194792Phase 2Results postedReport a problem
- Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast CancerCompletedNCT00066690Phase 3Results postedReport a problem
- Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By ExemestaneCompletedNCT00036270Phase 3Results postedReport a problem
- Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer PatientsCompletedNCT06009627Phase 2/3Report a problem
- Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast CancerCompletedNCT05150652Phase 2Report a problem
- Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast CancerStatus unknownNCT04997798Phase 2Report a problem
- Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer PatientsCompletedNCT04659551Phase 2Report a problem
- A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast CancerActive, not recruitingNCT04569747Phase 2Report a problem
- Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)Active, not recruitingNCT04383275Phase 2Report a problem
- Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)CompletedNCT03948568Phase 4Report a problem
- A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).CompletedNCT03355157Phase 4Report a problem
- Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer PatientsCompletedNCT03272477Phase 2Report a problem
- Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast CancerWithdrawnNCT03238703Phase 4Report a problem
- Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast CancerStatus unknownNCT03204734Phase 2Report a problem
- Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer PatientsCompletedNCT02995772Phase 3Report a problem
- CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast CancerActive, not recruitingNCT02918084Phase 3Report a problem
- Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast CancerCompletedNCT02820961Phase 1Report a problem
- Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node MetastasesActive, not recruitingNCT02603679Phase 2Report a problem
- A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBCStatus unknownNCT02592746Phase 2Report a problem
- Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer PatientsTerminatedNCT02532400Phase 3Report a problem
- Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast CancerStatus unknownNCT02404051Phase 3Report a problem
- Detect V / CHEVENDO (Chemo vs. Endo)Active, not recruitingNCT02344472Phase 3Report a problem
- Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With BevacizumabCompletedNCT02248571Phase 4Report a problem
- Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast CancerStatus unknownNCT02025712Phase 2Report a problem
- Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast CancerCompletedNCT01989780Phase 2Report a problem
- Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast CancerCompletedNCT01950182Phase 3Report a problem
- Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast CancerStatus unknownNCT01924078Phase 2Report a problem
- Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung CancerCompletedNCT01664754Phase 1Report a problem
- Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer PatientsCompletedNCT01638247Phase 3Report a problem
- Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast CancerCompletedNCT01612871Phase 4Report a problem
- ELBA: Exemestane and Lapatinib in Advanced Breast CancerWithdrawnNCT01005641Phase 2Report a problem
- Exemestane (Aromasine) + Tamoxifen - Breast Neo-AdjuvantCompletedNCT00919399Phase 2Report a problem
- Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast CancerCompletedNCT00893061Phase 3Report a problem
- Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor TherapyStatus unknownNCT00688194Phase 3Report a problem
- Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast CancerStatus unknownNCT00687648Phase 2Report a problem
- Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By SurgeryStatus unknownNCT00541086Phase 3Report a problem
- Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of DiseaseCompletedNCT00200174Not applicableReport a problem
- Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast CancerWithdrawnNCT00057993Phase 2Report a problem
- Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast CancerCompletedNCT00032136Phase 3Report a problem
- Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate CancerCompletedNCT00031889Phase 2Report a problem
- Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast CancerCompletedNCT00010010Phase 2Report a problem
- Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast CancerStatus unknownNCT00003418Phase 3Report a problem
- Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast CancerCompletedNCT00002777Phase 3Report a problem